<SEC-DOCUMENT>0001193125-25-127970.txt : 20250528
<SEC-HEADER>0001193125-25-127970.hdr.sgml : 20250528
<ACCEPTANCE-DATETIME>20250527175359
ACCESSION NUMBER:		0001193125-25-127970
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20250526
FILED AS OF DATE:		20250528
DATE AS OF CHANGE:		20250527

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			IMMUTEP Ltd
		CENTRAL INDEX KEY:			0001506184
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			C3
		FISCAL YEAR END:			0630

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35428
		FILM NUMBER:		25990198

	BUSINESS ADDRESS:	
		STREET 1:		LEVEL 32, SUITE 32.07 AUSTRALIA SQUARE
		STREET 2:		264 GEORGE STREET
		CITY:			SYDNEY,
		STATE:			C3
		ZIP:			NSW 2000
		BUSINESS PHONE:		612 8315 7003

	MAIL ADDRESS:	
		STREET 1:		LEVEL 32, SUITE 32.07 AUSTRALIA SQUARE
		STREET 2:		264 GEORGE STREET
		CITY:			SYDNEY,
		STATE:			C3
		ZIP:			NSW 2000

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Prima BioMed Ltd
		DATE OF NAME CHANGE:	20101119
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>d51427d6k.htm
<DESCRIPTION>6-K
<TEXT>
<HTML><HEAD>
<TITLE>6-K</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
<DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;
</DIV><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV> <P STYLE="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>Washington, D.C. 20549 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM&nbsp;6-K </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>REPORT OF FOREIGN PRIVATE ISSUER </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>PURSUANT TO RULE&nbsp;13a-16 OR 15d-16 </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>UNDER THE SECURITIES EXCHANGE ACT OF 1934 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Date as May&nbsp;26, 2025 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission File Number&nbsp;001-35428 </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>IMMUTEP LIMITED </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact
Name as Specified in its Charter) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>N/A </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Translation of
Registrant&#146;s Name) </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Level&nbsp;32, Australia Square </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>264 George Street, Sydney </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>NSW 2000, Australia </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(Address of principal executive office) </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center><DIV STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</DIV></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant files or will file annual reports under cover of Form&nbsp;20-F or Form&nbsp;40-F. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Form 20-F&#8194;&#9746;&#8195;&#8195;&#8195;Form 40-F&#8194;&#9744; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form&nbsp;6-K in paper as permitted by Regulation&nbsp;S-T Rule&nbsp;101(b)(1):&#8194;&#9744; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark if the registrant is submitting the Form&nbsp;6-K in paper as permitted by Regulation&nbsp;S-T Rule&nbsp;101(b)(7):&#8194;&#9744; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether by furnishing the information contained in this Form, the registrant is also thereby furnishing the information to the
Commission pursuant to Rule&nbsp;12g3-2(b) under the Securities Exchange Act of 1934. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Yes&#8194;&#9744;&#8195;&#8195;&#8195;No&#8194;&#9746; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If &#147;Yes&#148; is marked, indicated below the file number assigned to the registrant in connection with Rule&nbsp;12g3-2(b): Not applicable. </P>
<P STYLE="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;
</DIV><DIV STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</DIV>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT INDEX </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="5%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="94%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Exhibit</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman; "><B>Description&nbsp;of&nbsp;Exhibit</B></P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">99.1</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman"><A HREF="d51427dex991.htm">Immutep&#146;s Efti with Radiotherapy &amp; KEYTRUDA<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> (pembrolizumab)
 Meets Primary Endpoint in Phase&nbsp;II for Soft Tissue Sarcoma </A></P></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned, thereunto duly authorized. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Date: May&nbsp;26, 2025 </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">IMMUTEP LIMITED</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Marc Voigt</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Marc Voigt</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">Chief Executive Officer</TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>d51427dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g51427immutep.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g51427rule.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Immutep&#146;s Efti with Radiotherapy&nbsp;&amp;
KEYTRUDA<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> (pembrolizumab) Meets </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Primary Endpoint in Phase II for Soft
Tissue Sarcoma </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Novel combination with efti has met the trial&#146;s primary endpoint of tumour hyalinization/fibrosis in the
neoadjuvant setting for patients with resectable soft tissue sarcoma </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="1%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">Detailed results are planned for presentation at a future medical meeting </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>SYDNEY, AUSTRALIA &#150; May</B><B></B><B>&nbsp;26, </B><B>2025 &#150;</B> <U>Immutep Limited</U> (ASX: IMM; NASDAQ: IMMP) (&#147;Immutep&#148; or
&#147;the Company&#148;), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces the investigator-initiated <FONT STYLE="white-space:nowrap">EFTISARC-NEO</FONT> Phase II trial evaluating eftilagimod alfa (efti)
with radiotherapy plus KEYTRUDA<SUP STYLE="font-size:75%; vertical-align:top">&reg;</SUP> (pembrolizumab) in the neoadjuvant setting for resectable soft tissue sarcoma (STS) has met its primary endpoint. The novel combination significantly exceeded
the study&#146;s prespecified median of 35% tumour hyalinization/fibrosis versus 15% for historical data from radiotherapy alone in patients with resectable soft tissue sarcoma (STS). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Tumour hyalinization/fibrosis is an early surrogate endpoint at the time of surgical resection that has been associated with improved overall survival and
recurrence-free survival for STS patients.<SUP STYLE="font-size:75%; vertical-align:top">1,2</SUP> The trial&#146;s investigators at the Maria Sk&#322;odowska-Curie National Research Institute of Oncology (MSCNRIO) in Warsaw, the national reference
centre for STS in Poland, plan to present detailed results from the study at a future medical meeting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Katarzyna Kozak, M.D., Ph.D., and
Pawe</B><B>&#322;</B><B> Sobczuk, M.D., Ph.D., medical oncologists at the Department of Soft Tissue/Bone Sarcoma and Melanoma at MSCNRIO </B>and the trial&#146;s principal investigators, said: &#147;It is very encouraging to see the
chemotherapy-free combination with efti far exceed the ambitious target we initially set for the trial&#146;s primary endpoint in resectable soft tissue sarcoma. These results support our belief that efti&#146;s activation of antigen-presenting
cells, and in turn a broad adaptive and innate immune response, helps transform the immunosuppressed tumour microenvironment of soft tissue sarcomas leading to strong anti-cancer efficacy. There remains a very high unmet need in this aggressive
orphan cancer indication and we look forward to presenting detailed results at a medical meeting later this year.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As <U>previously announced at the
Connective Tissue Oncology Society (CTOS) Annual Meeting in November 2024,</U> the combination therapy demonstrated significant efficacy with a median of 50% tumour hyalinization/fibrosis in a preliminary analysis of 21 patients with resectable STS
available for primary endpoint assessment. The <FONT STYLE="white-space:nowrap">EFTISARC-NEO</FONT> study, which is primarily funded with a grant from the Polish government awarded by the Polish Medical Research Agency program, subsequently
completed enrolment of 40 patients in January 2025. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">STS is an orphan disease with high unmet medical need and a poor prognosis for patients. The
incidence of STS varies in different regions globally. In the United States, the number of new STS cases in 2025 is estimated to be ~13,520 with ~5,420 deaths, according to the American Cancer
Society.<SUP STYLE="font-size:75%; vertical-align:top">3</SUP> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For more information on <FONT STYLE="white-space:nowrap">EFTISARC-NEO,</FONT> visit
clinicaltrials.gov (NCT06128863). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Eftilagimod Alfa (efti) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Efti is Immutep&#146;s proprietary soluble <FONT STYLE="white-space:nowrap">LAG-3</FONT> protein and MHC Class&nbsp;II agonist that stimulates both innate and
adaptive immunity for the treatment of cancer. As a <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">first-in-class</FONT></FONT> antigen presenting cell (APC) activator, efti binds to MHC (major histocompatibility complex)
Class&nbsp;II molecules on APC leading to activation and proliferation of CD8+ cytotoxic T cells, CD4+ helper T cells, dendritic cells, NK cells, and monocytes. It also upregulates the expression of key biological molecules like <FONT
STYLE="white-space:nowrap">IFN-&#436;</FONT> and CXCL10 that further boost the immune system&#146;s ability to fight cancer. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="right">


<IMG SRC="g51427immutep.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g51427rule.jpg" ALT="LOGO">
 </P> <P STYLE="font-size:12pt; margin-top:0pt; margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Efti is under evaluation for a variety of solid
tumours including <FONT STYLE="white-space:nowrap">non-small</FONT> cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), and metastatic breast cancer. Its favourable safety profile enables various combinations, including with <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">anti-PD-[L]1</FONT></FONT> immunotherapy and/or chemotherapy. Efti has received Fast Track designation in first line HNSCC and in first line NSCLC from the United States Food and Drug
Administration (FDA). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Immutep </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Immutep is a
late-stage biotechnology company developing novel immunotherapies for cancer and autoimmune disease. The Company is a pioneer in the understanding and advancement of therapeutics related to Lymphocyte Activation
<FONT STYLE="white-space:nowrap">Gene-3</FONT> <FONT STYLE="white-space:nowrap">(LAG-3),</FONT> and its diversified product portfolio harnesses <FONT STYLE="white-space:nowrap">LAG-3&#146;s</FONT> ability to stimulate or suppress the immune
response. Immutep is dedicated to leveraging its expertise to bring innovative treatment options to patients in need and to maximise value for shareholders. For more information, please visit <U>www.immutep.com</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>1. Schaefer IM et al. Histologic Appearance After Preoperative Radiation Therapy for Soft Tissue Sarcoma: Assessment of the European Organization for
Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group Response Score. Int J Radiat Oncol Biol Phys. 2017 Jun <FONT STYLE="white-space:nowrap">1;98(2):375-383.</FONT> doi: 10.1016/j.ijrobp.2017.02.087. Epub 2017 Feb 24. PMID: 28463157.
</I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>2. Rao SR et al. Extent of tumor fibrosis/hyalinization and infarction following neoadjuvant radiation therapy is associated with improved survival
in patients with soft-tissue sarcoma. Cancer Med. 2022 <FONT STYLE="white-space:nowrap">Jan;11(1):194-206.</FONT> doi: 10.1002/cam4.4428. Epub 2021 Nov 27. PMID: 34837341; PMCID: PMC8704179. </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>3. American Cancer Society statistics:
<FONT STYLE="white-space:nowrap">https://www.cancer.org/cancer/types/soft-tissue-sarcoma/about/key-statistics.html</FONT> </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>KEYTRUDA<SUP
STYLE="font-size:75%; vertical-align:top">&reg;</SUP> is a registered trademark of Merck Sharp&nbsp;&amp; Dohme LLC, a subsidiary of Merck<SUB STYLE="font-size:75%; vertical-align:bottom"></SUB>&nbsp;&amp; Co., Inc., Rahway, NJ, USA. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Australian Investors/Media: </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Catherine Strong,
Sodali&nbsp;&amp; Co. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+61 (0)406 759 268; <U>catherine.strong@sodali.com</U> </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>U.S. Media: </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chris Basta, VP, Investor Relations and
Corporate Communications </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">+1 (631) 318 4000; <U>chris.basta@immutep.com</U> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This announcement was authorised for release by the CEO of Immutep Limited. </P>
<P STYLE="margin-top:120pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Immutep Limited</B>, Level&nbsp;32, Australia Square, 264 George Street, Sydney NSW 2000, Australia </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ABN: 90 009 237 889 </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g51427immutep.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g51427immutep.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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M P$  A$#$0 _ /W\H * "@ H * "@ H * "@ H * "@ H * "@ H * "@ H
M* "@ H * "@ H .GX4FU%=D@7W'*>+?&GA_P1I;ZMX@OH[2W4F."%2)+N\G
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M52O1ALKITVIU??E%Z*UE^MSU\IX5H8*I'$8J2KU8ZQCR647WNY2O]R/IY5V
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M4"HR*!:?(&M+=#Z)P!^']*!62^0  >V/PQBG?\ 22=]F+2&<1\2O^2>^.?\
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M *^U?S/T;\2PI/X;UZ&0;HY-$U2-U/1D>QG5E8=Q@U]/4TI5/*,OR9^K8O\
MW;%=/W53_P!(9^=WP!=E^+/A502 XUM'QQE1X=U9P/\ OI%/X5\WEVF*AZ/\
MC\LX57+G.&Z:3_(^_P#QR@?P3XNC(!5O"VO(0>A!TJ[!&/H:^DK?P:W^$_3L
M?_N..7:C5_)GPM^S>2OQ.M /E_XE&KJ>V0L*8'YJ#^%?.Y3IC5_AE^I^:<(:
M9S3_ .O<OS9K_MW?\>?PR]KGQ9^L7A['\C7TQ^KGKW['C _!33 #]W7M?!]B
M;P$#ZX(/XT >8_MT_P#(N^ /^PUK/_I!:4 =+^Q!_P DM\0?]E U3_U&_"]
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M29/$WCV!2PMY-$T>:50?D\^"^N$MR?1A'/<X_P!YO6@#]*Z "@ H XCXE?\
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MTZ_T:7Q';:UIVL6]UJ$,5]X4O-4TO5["UGLKNS9@-2TN98KIEP\120PH7VJ
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MY!MY#[[PRE[X7L_#37,D<=I'HD0NEC4R,-$N[&ZB)B+ #S38*K?,=OF'&<4
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:&.615"-*5!#'(&:-@V/1Z "@ H * "@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g51427rule.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g51427rule.jpg
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M 0$! 0$! 0        $" P0%!@<("0H+$  " 0,# @0#!04$!    7T! @,
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MX:4^)G_/71/_  5M_P#)5']JXOO#^OF'^M^;]J/_ ("O\P_X:4^)G_/71/\
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M$_"G_H4H/_!CK'_RPH^H8'_H%A^(?ZLY+_T!1^]A_P *)^%/_0I0?^#'6/\
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ML?\ RPH^H8'_ *!8?B'^K.2_] 4?O8?\*)^%/_0I0?\ @QUC_P"6%'U# _\
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M_A1/PI_Z%*#_ ,&.L?\ RPH^H8'_ *!8?B'^K.2_] 4?O8?\*)^%/_0I0?\
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MCZA@?^@6'XA_JSDO_0%'[V'_  HGX4_]"E!_X,=8_P#EA1]0P/\ T"P_$/\
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M#_T"P_$/]6<E_P"@*/WL/^%$_"G_ *%*#_P8ZQ_\L*/J&!_Z!8?B'^K.2_\
M0%'[V'_"B?A3_P!"E!_X,=8_^6%'U# _] L/Q#_5G)?^@*/WL/\ A1/PI_Z%
M*#_P8ZQ_\L*/J&!_Z!8?B'^K.2_] 4?O8?\ "B?A3_T*4'_@QUC_ .6%'U#
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A93M^/^HAK';_ +B-/^S\!_T"QT]2X\-9(HI?4(:>;/_9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
